Your search returned 719 results.

Results
	541.	A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. [electronic resource] by Park, Ji Soo Hong, Min Hee Chun, You Jin Kim, Hye Ryun Cho, Byoung Chul Producer: 20200622 In: Lung cancer (Amsterdam, Netherlands) vol. 134 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	542.	Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer. [electronic resource] by Sano, Kazumi Nakadate, Kazuhiko Hanada, Kazuhiko Producer: 20210104 In: BMC cancer vol. 20 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	543.	Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. [electronic resource] by Solca, Flavio Dahl, Goeran Zoephel, Andreas Bader, Gerd Sanderson, Michael Klein, Christian Kraemer, Oliver Himmelsbach, Frank Haaksma, Eric Adolf, Guenther R Producer: 20121231 In: The Journal of pharmacology and experimental therapeutics vol. 343 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	544.	Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study. [electronic resource] by Wada, Yosuke Koyama, Shigeru Kuraishi, Hiroshi Miyahara, Takashige Yoshiike, Fumiaki Agatsuma, Toshihiko Yamamoto, Ryouhei Ono, Yasushi Suzuki, Toshiro Hachiya, Tsutomu Gomi, Daisuke Tateishi, Kazunari Hanaoka, Masayuki Koizumi, Tomonobu Producer: 20170508 In: Respiratory investigation vol. 54 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	545.	Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. [electronic resource] by Oda, Naohiro Ichihara, Eiki Hotta, Katsuyuki Ninomiya, Kiichiro Ninomiya, Takashi Kubo, Toshio Minami, Daisuke Murakami, Toshi Yokoyama, Toshihide Harada, Daijiro Kuyama, Shoichi Ichikawa, Hirohisa Inoue, Koji Kishino, Daizo Inoue, Masaaki Takigawa, Nagio Shibayama, Takuo Harita, Shingo Tanimoto, Mitsune Kiura, Katsuyuki Producer: 20170926 In: Clinical lung cancer vol. 18 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	546.	P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. [electronic resource] by Zhang, Yan Wang, Changyuan Liu, Zhihao Meng, Qiang Huo, Xiaokui Liu, Qi Sun, Pengyuan Yang, Xiaobo Sun, Huijun Ma, Xiaodong Liu, Kexin Producer: 20180912 In: Pharmacological reports : PR vol. 70 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	547.	EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. [electronic resource] by Oshima, Yasuo Tanimoto, Tetsuya Yuji, Koichiro Tojo, Arinobu Producer: 20190930 In: JAMA oncology vol. 4 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	548.	[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs]. [electronic resource] by Komada, Fusao Producer: 20180228 In: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan vol. 138 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	549.	Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. [electronic resource] by Ninomiya, Takashi Ishikawa, Nobuhisa Inoue, Koji Kubo, Toshio Yasugi, Masayuki Shibayama, Takuo Maeda, Tadashi Fujitaka, Kazunori Kodani, Masahiro Yokoyama, Toshihide Kuyama, Shoichi Ochi, Nobuaki Ueda, Yutaka Miyoshi, Seigo Kozuki, Toshiyuki Amano, Yoshihiro Kubota, Tetsuya Sugimoto, Keisuke Bessho, Akihiro Ishii, Tomoya Watanabe, Kazuhiko Oze, Isao Hotta, Katsuyuki Kiura, Katsuyuki Producer: 20190625 In: Clinical lung cancer vol. 20 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	550.	Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan. [electronic resource] by Graham, Jonathan Earnshaw, Stephanie Burslem, Kate Lim, Jonathan Producer: 20181010 In: Journal of managed care & specialty pharmacy vol. 24 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	551.	Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System. [electronic resource] by Huang, Jing Meng, Long Yang, Bing Sun, Shusen Luo, Zhigang Chen, Hong Producer: 20201208 In: Scientific reports vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	552.	Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. [electronic resource] by Nanjo, Shigeki Yamada, Tadaaki Nishihara, Hiroshi Takeuchi, Shinji Sano, Takako Nakagawa, Takayuki Ishikawa, Daisuke Zhao, Lu Ebi, Hiromichi Yasumoto, Kazuo Matsumoto, Kunio Yano, Seiji Producer: 20150223 In: PloS one vol. 8 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	553.	Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States. [electronic resource] by Samuelsen, Carl Lim, Jonathan Golembesky, Amanda Shrestha, Sulena Wang, Li Griebsch, Ingolf Producer: 20200630 In: Journal of medical economics vol. 23 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	554.	Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling. [electronic resource] by Shu, Degui Xu, Yufen Chen, Wenyu Producer: 20210716 In: Journal of drug targeting vol. 28 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	555.	Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. [electronic resource] by Cappuzzo, Federico Soo, Ross Hochmair, Maximilian Schuler, Martin Lam, Kwok Chi Stehle, Gerd Cseh, Agnieszka Lorence, Robert M Linden, Stephan Forman, Nicole D Hilbe, Wolfgang Jazieh, Abdul Rahman Tsai, Chun-Ming Producer: 20181024 In: Future oncology (London, England) vol. 14 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	556.	Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. [electronic resource] by Ocaña, Alberto Amir, Eitan Producer: 20091208 In: Cancer treatment reviews vol. 35 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	557.	The search for improved systemic therapy of non-small cell lung cancer--what are today's options? [electronic resource] by Früh, M Producer: 20110908 In: Lung cancer (Amsterdam, Netherlands) vol. 72 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	558.	EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. [electronic resource] by Kobayashi, Yoshihisa Togashi, Yosuke Yatabe, Yasushi Mizuuchi, Hiroshi Jangchul, Park Kondo, Chiaki Shimoji, Masaki Sato, Katsuaki Suda, Kenichi Tomizawa, Kenji Takemoto, Toshiki Hida, Toyoaki Nishio, Kazuto Mitsudomi, Tetsuya Producer: 20160915 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 21 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	559.	EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. [electronic resource] by Gallant, Jean-Nicolas Sheehan, Jonathan H Shaver, Timothy M Bailey, Mark Lipson, Doron Chandramohan, Raghu Red Brewer, Monica York, Sally J Kris, Mark G Pietenpol, Jennifer A Ladanyi, Marc Miller, Vincent A Ali, Siraj M Meiler, Jens Lovly, Christine M Producer: 20160819 In: Cancer discovery vol. 5 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	560.	Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population. [electronic resource] by Sluga, Romina VAN DEN Borne, Ben E E M Roepman, Paul Peters, Bas J M Kastelijn, Elisabeth A Schramel, Franz M N H Producer: 20180104 In: Anticancer research vol. 38 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

First
Previous
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
Next
Last

Refine your search

Availability

Authors

Topics

Languages

Your search returned 719 results.